Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ANVS Annovis Bio, Inc.

Market Closed 11-13 16:00:00 EST

0.9261

+0.0789

+9.31%

盘后0.9217

-0.0044-0.48%

19:30 EST

High0.9510	Low0.8142	Vol2.20M
Open0.8850	D1 Closing0.8472	Amplitude16.15%
Mkt Cap57.44M	Tradable Cap50.14M	Total Shares62.02M
T/O1.98M	T/O Rate4.06%	Tradable Shares54.14M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ANVS","market":"US","secType":"STK","nameCN":"Annovis Bio, Inc.","latestPrice":0.9261,"timestamp":1794603600000,"preClose":0.8472,"halted":0,"volume":2197106,"hourTrading":{"tag":"盘后","latestPrice":0.9217,"preClose":0.9261,"latestTime":"19:30 EST","volume":57453,"amount":53696.008977,"timestamp":1794616221292,"change":-0.0044,"changeRate":-0.004751,"amplitude":0.0406},"delay":0,"changeRate":0.09313031161473098,"floatShares":54137554,"shares":62022500,"eps":-1.789521,"marketStatus":"Market Closed","change":0.0789,"latestTime":"11-13 16:00:00 EST","open":0.885,"high":0.951,"low":0.8142,"amount":1984235.2106886,"amplitude":0.161473,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.789521,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1794819600000},"marketStatusCode":7,"adr":0,"listingDate":1580274000000,"exchange":"NYSE","adjPreClose":0.8472,"preHourTrading":{"tag":"盘前","latestPrice":0.8718,"preClose":0.8472,"latestTime":"09:24 EST","volume":10646,"amount":9173.8807014,"timestamp":1794579874634,"change":0.0246,"changeRate":0.029037,"amplitude":0.032578},"postHourTrading":{"tag":"盘后","latestPrice":0.9217,"preClose":0.9261,"latestTime":"19:30 EST","volume":57453,"amount":53696.008977,"timestamp":1794616221292,"change":-0.0044,"changeRate":-0.004751,"amplitude":0.0406},"volumeRatio":0.513941331015352,"impliedVol":1.2375,"impliedVolPercentile":0.6853},"requestUrl":"/m/hq/s/ANVS/wiki","defaultTab":"wiki","newsList":[{"id":"2683555636","title":"Annovis Bio Presents Buntanetap Development Update, Targets Alzheimer’s Drug Application in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2683555636","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683555636?lang=en_us&edition=fundamental","pubTime":"2026-11-14 22:09","pubTimestamp":1794665363,"startTime":"0","endTime":"0","summary":"Annovis Bio Presents Buntanetap Development Update, Targets Alzheimer’s Drug Application in 2027Annovis Bio expects symptomatic data from its Phase 3 DUET-AD Alzheimer's trial in Q1 2027.The approval ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261114:nNDLbpJ077:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683501614","title":"Annovis Bio Inc Reports Results for the Quarter Ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2683501614","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683501614?lang=en_us&edition=fundamental","pubTime":"2026-11-13 23:08","pubTimestamp":1794582486,"startTime":"0","endTime":"0","summary":"Annovis Bio Inc reports results for the quarter ended September 30 - Earnings SummaryAnnovis Bio IncANVS.Nreported a quarterly adjusted loss of 22 cents per share for the quarter ended September 30, h","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261113:nL5N46U1TX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683503111","title":"Annovis Bio Q3 EPS $(0.22) Beats $(0.32) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2683503111","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683503111?lang=en_us&edition=fundamental","pubTime":"2026-11-13 21:09","pubTimestamp":1794575343,"startTime":"0","endTime":"0","summary":"Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.32) by 31.25 percent. This is a 40.54 percent increase over losses of $(0.37) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/11/63235316/annovis-bio-q3-eps-0-22-beats-0-32-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683503621","title":"Annovis Bio Q3 EPS USD -0.22","url":"https://stock-news.laohu8.com/highlight/detail?id=2683503621","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683503621?lang=en_us&edition=fundamental","pubTime":"2026-11-13 21:05","pubTimestamp":1794575111,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261113:nPLXHL3Z5J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683503318","title":"Press Release: Annovis Provides Corporate Updates and Reports Third Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2683503318","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683503318?lang=en_us&edition=fundamental","pubTime":"2026-11-13 21:00","pubTimestamp":1794574800,"startTime":"0","endTime":"0","summary":"-- Last patient, last visit of the 6-month treatment period in the Phase 3. DUET-AD study is scheduled for December 31, 2026, with database lock on. -- Parkinson's disease open-label extension  study has enrolled 326. patients, with enrollment scheduled to close on January 29, 2027. -- Annovis raised $21.0 million in gross proceeds through an underwritten. public offering, which is expected to fund operations through the 6-month. unique design with two prespecified data readouts -- at 6 months. -- Enrollment: DUET-AD is fully enrolled, with 862 patients who have early. AD  and are positive for the plasma biomarker pTau217.Alzheimer's disease -- open-label extension -- Activation: The OLE-AD study will use the same clinical sites as DUET-AD.The rollover of patients from DUET-AD into OLE-AD is expected to start by. buntanetap after completing their 18-month treatment period. Patients. from both arms -- buntanetap and placebo -- will be allowed to join. The. OLE-AD study is also open to p","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS","BK4023","BK4139","DBS","LU1169590202.USD","AD","LU1169589451.USD","BK4132","PD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682759999","title":"Annovis Bio Receives U.S. Patent for New Crystalline Form of Buntanetap","url":"https://stock-news.laohu8.com/highlight/detail?id=2682759999","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682759999?lang=en_us&edition=fundamental","pubTime":"2026-11-12 21:08","pubTimestamp":1794488904,"startTime":"0","endTime":"0","summary":"Annovis Bio Receives U.S. Patent for New Crystalline Form of BuntanetapAnnovis Bio received a U.S. patent November 3, 2026, covering buntanetap Form B, with protection through June 21, 2044.Form B is ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nNDL6g7FyB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2095319765.USD","LU0314104364.USD","LU2210149790.SGD","BK4588","BK4112","SG9999014013.SGD","SG9999014039.USD","SG9999014005.SGD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00BQXX3C00.GBP","BCDF","IE00B64PRP62.GBP","BK4585","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BN0W2W23.USD","NDAQ","IE00BKPKM429.USD","SG9999014021.USD","ANVS","IE00BQXX3F31.USD","IE00BQXX3D17.EUR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682800668","title":"Annovis Bio Expects Cash to Fund Operations Through March 2027 Alzheimer's Trial Readout","url":"https://stock-news.laohu8.com/highlight/detail?id=2682800668","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682800668?lang=en_us&edition=fundamental","pubTime":"2026-11-09 20:11","pubTimestamp":1794226268,"startTime":"0","endTime":"0","summary":"Annovis Bio expects cash to fund operations through March 2027 Alzheimer's trial readoutAnnovis Bio expects offering proceeds and existing cash to fund operations through its pivotal Phase 3 Alzheimer","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261109:nNDL7K7nRc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00B3QW5Z07.USD","ANVS","BK4585","SG9999014039.USD","IE00BQXX3D17.EUR","IE00BQXX3C00.GBP","LU2210149790.SGD","SG9999014021.USD","LU2095319765.USD","SG9999014005.SGD","IE00BN0W2W23.USD","BK4139","IE00B64PRP62.GBP","SG9999014013.SGD","LU2210150020.SGD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","BCDF","LU0314104364.USD","IE00BQXX3F31.USD","NDAQ","BK4112","BK4588","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682807375","title":"Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2682807375","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682807375?lang=en_us&edition=fundamental","pubTime":"2026-11-09 20:00","pubTimestamp":1794225601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261109:nTUA1PQYQM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681828394","title":"Bullish Annovis Bio Insider Buying Worth US$7.10m Yet To Pay Off","url":"https://stock-news.laohu8.com/highlight/detail?id=2681828394","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681828394?lang=en_us&edition=fundamental","pubTime":"2026-11-08 20:30","pubTimestamp":1794141023,"startTime":"0","endTime":"0","summary":"SSimply Wall StNovember 8, 2026","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-anvs/annovis-bio/news/bullish-annovis-bio-insider-buying-worth-us710m-yet-to-pay-o","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-anvs/annovis-bio/news/bullish-annovis-bio-insider-buying-worth-us710m-yet-to-pay-o","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ANVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681717894","title":"Annovis Bio Director Michael B Hoffman Reports $5 Million Common Share Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2681717894","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681717894?lang=en_us&edition=fundamental","pubTime":"2026-11-07 05:31","pubTimestamp":1794000706,"startTime":"0","endTime":"0","summary":"Annovis Bio Director Michael B Hoffman Reports $5 Million Common Share AcquisitionAnnovis Bio director Michael B. Hoffman purchased 5,000,000 shares of common stock, bringing his direct holdings to 8,","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261106:nNDL9j5Jzj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Annovis Bio Director Michael B Hoffman Reports $5 Million Common Share Acquisition","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681914889","title":"Annovis Bio Announces Pricing of Public Offering and Underwriting Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2681914889","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681914889?lang=en_us&edition=fundamental","pubTime":"2026-11-06 07:29","pubTimestamp":1793921363,"startTime":"0","endTime":"0","summary":"Annovis Bio ( ($ANVS) ) has issued an announcement. On November 4, 2026, Annovis Bio announced the launch of a public offering, and on November 5, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/annovis-bio-announces-pricing-of-public-offering-and-underwriting-agreement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/annovis-bio-announces-pricing-of-public-offering-and-underwriting-agreement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681079590","title":"Annovis Bio 21M share Spot Secondary priced at $1.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2681079590","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681079590?lang=en_us&edition=fundamental","pubTime":"2026-11-05 22:01","pubTimestamp":1793887276,"startTime":"0","endTime":"0","summary":"Canaccord is acting as sole book running manager for the offering. The deal priced below last closing price of $1.21. Published first on TheFly – t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/annovis-bio-21m-share-spot-secondary-priced-at-1-00-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/annovis-bio-21m-share-spot-secondary-priced-at-1-00-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681107617","title":"Annovis Bio Slumps on $21 Mln Stock Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2681107617","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681107617?lang=en_us&edition=fundamental","pubTime":"2026-11-05 21:47","pubTimestamp":1793886442,"startTime":"0","endTime":"0","summary":"BUZZ-Annovis Bio slumps on $21 mln stock sale** Annovis Bio'sANVS.Nshares slump 30% to record low of 85 cents premarket after $21 mln equity raise** Malvern, Pennsylvania-based biotech sells 21 mln shares including pre-funded warrants at $1** Offering price represents 17.4% discount to stock's last close** Co also issues accompanying warrants to purchase up to 21 mln shares; those 5-yr warrants are exercisable immediately at exercise price of $1** ANVS intends to use net offering proceeds for clinical development of its lead drug, buntanetap, in clinical studies for Alzheimer’s disease and Parkinson's disease, and for working capital and general purposes** Canaccord Genuity sole bookrunner** Co has ~43 mln shares outstanding as of Nov 3** Through Weds, shares shed 65% YTD** All 4 analysts covering the stock rate it \"buy\"; median PT $9, per LSEG data","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nL6N46M11N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681073578","title":"Annovis Announces Pricing of $21.0 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2681073578","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681073578?lang=en_us&edition=fundamental","pubTime":"2026-11-05 21:05","pubTimestamp":1793883934,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nTUA28RLDH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681785490","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2681785490","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681785490?lang=en_us&edition=fundamental","pubTime":"2026-11-05 20:45","pubTimestamp":1793882739,"startTime":"0","endTime":"0","summary":"MNTN  stock was 45% lower pre-bell Thursday after the company posted higher Q3 earnings and revenue.Veracyte  shares were down 29%, a day after the company reported its Q3 financial results.Annovis Bio  stock was 24% lower after the company announced a proposed underwritten public offering of common stock and warrants.Akebia Therapeutics  shares were down 26% after the company posted a Q3 loss amid lower revenue.BuzzFeed  stock was 24% lower following the company's Q3 financial results.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BZFD","BK4111","ANVS","VCYT","BK4587","AKBA","BK4077","FBT","MNTN","BK4009","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681310096","title":"Annovis Bio Files Charter Amendment After Stockholder Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2681310096","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681310096?lang=en_us&edition=fundamental","pubTime":"2026-11-05 05:57","pubTimestamp":1793829466,"startTime":"0","endTime":"0","summary":"Annovis Bio ( ($ANVS) ) just unveiled an update. On November 3, 2026, Annovis Bio stockholders approved increasing authorized common shares from 70...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/annovis-bio-files-charter-amendment-after-stockholder-approval?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/annovis-bio-files-charter-amendment-after-stockholder-approval?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANVS","LU0130103400.USD","LU1201861165.SGD","LU0211331839.USD","LU0130517989.USD","BK4585","LU0130102774.USD","BK4559","LU0980610538.SGD","LU0289960550.SGD","CHTR","BK4588","BK4100","LU0477156797.USD","LU0070302665.USD","BK4534","LU0648000940.SGD","LU0320765489.SGD","BK4139","LU0477156953.USD","LU0175139822.USD","LU1201861249.SGD","LU0208291251.USD","LU0648001328.SGD","LU0130518102.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681093624","title":"Annovis Bio Launches Proposed Public Offering of Common Stock and Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2681093624","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681093624?lang=en_us&edition=fundamental","pubTime":"2026-11-05 05:33","pubTimestamp":1793828023,"startTime":"0","endTime":"0","summary":"Annovis Bio Launches Proposed Public Offering of Common Stock and WarrantsAnnovis Bio launched a proposed underwritten public offering of common stock or pre-funded warrants, with accompanying warrant","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nNDL2qVTW0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BQXX3C00.GBP","SG9999014021.USD","IE00BN0W2W23.USD","BK4112","BK4139","IE00BQXX3D17.EUR","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00BQXX3F31.USD","LU2095319765.USD","LU2210150020.SGD","BK4585","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4588","SG9999014005.SGD","BCDF","SG9999014039.USD","SG9999014013.SGD","ANVS","IE00BGHQF748.EUR","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681982350","title":"Annovis Bio Holds Special Stockholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2681982350","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681982350?lang=en_us&edition=fundamental","pubTime":"2026-11-05 05:28","pubTimestamp":1793827706,"startTime":"0","endTime":"0","summary":"Annovis Bio Holds Special Stockholder MeetingAnnovis Bio shareholders approved increasing authorized Common Stock from 70,000,000 to 140,000,000 shares at the November 3, 2026, special meeting.The cha","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nNDL62V2h4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681606764","title":"Annovis Bio - to Use Net Proceeds for Buntanetap Development and Corporate Purposes","url":"https://stock-news.laohu8.com/highlight/detail?id=2681606764","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681606764?lang=en_us&edition=fundamental","pubTime":"2026-11-05 05:07","pubTimestamp":1793826420,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nTUA5KRV8N:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681067936","title":"Annovis Bio - to Offer Shares, Pre-Funded Warrants, and Accompanying Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2681067936","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681067936?lang=en_us&edition=fundamental","pubTime":"2026-11-05 05:07","pubTimestamp":1793826420,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nTUA5KRV8N:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.annovisbio.com","stockEarnings":[{"period":"1week","weight":0.0961},{"period":"1month","weight":-0.0921},{"period":"3month","weight":-0.4994},{"period":"6month","weight":-0.5504},{"period":"1year","weight":-0.5956},{"period":"ytd","weight":-0.7323}],"compareEarnings":[{"period":"1week","weight":0.0259},{"period":"1month","weight":-0.0198},{"period":"3month","weight":-0.0283},{"period":"6month","weight":0.0206},{"period":"1year","weight":0.1225},{"period":"ytd","weight":0.1062}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.040659},{"month":2,"riseRate":0.285714,"avgChangeRate":0.058949},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.056117},{"month":4,"riseRate":0.142857,"avgChangeRate":-0.132244},{"month":5,"riseRate":0.571429,"avgChangeRate":0.255652},{"month":6,"riseRate":0.428571,"avgChangeRate":0.139284},{"month":7,"riseRate":0.571429,"avgChangeRate":0.075716},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.062756},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.087505},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.078357},{"month":11,"riseRate":0.571429,"avgChangeRate":0.204134},{"month":12,"riseRate":0.333333,"avgChangeRate":0.124011}],"exchange":"NYSE","name":"Annovis Bio, Inc.","nameEN":"Annovis Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Annovis Bio, Inc.(ANVS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Annovis Bio, Inc.,ANVS,Annovis Bio, Inc.股票,Annovis Bio, Inc.股票老虎,Annovis Bio, Inc.股票老虎国际,Annovis Bio, Inc.行情,Annovis Bio, Inc.股票行情,Annovis Bio, Inc.股价,Annovis Bio, Inc.股市,Annovis Bio, Inc.股票价格,Annovis Bio, Inc.股票交易,Annovis Bio, Inc.股票购买,Annovis Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Annovis Bio, Inc.(ANVS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}